Echo IQ Limited (ASX:EIQ)
Australia · Delayed Price · Currency is AUD | Market Cap | 951.83M +600.8% |
| Revenue (ttm) | 1.37M -18.2% |
| Net Income | -18.57M |
| EPS | -0.03 |
| Shares Out | 740.72M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,205,790 |
| Open | 1.300 |
| Previous Close | 1.285 |
| Day's Range | 1.282 - 1.312 |
| 52-Week Range | 0.165 - 1.875 |
| Beta | 0.14 |
| Analysts | Buy |
| Price Target | 1.90 (+47.86%) |
| Earnings Date | Sep 4, 2026 |
About Echo IQ
Echo IQ Limited engages in the provision of artificial intelligence (AI) diagnostics tool that enhance the diagnosis of structural heart disease in Australia. It offers EchoSolv, provides an AI-powered risk assessment of structural heart disease, including aortic stenosis, diastolic dysfunction, and heart failure. The company has a research collaboration with Mayo Clinic to evaluate echo IQ's proprietary artificial intelligence platform for cardiac risk stratification in oncology patients. The company was formerly known as Houston We Have Limit... [Read more]
Financial Performance
In fiscal year 2026, Echo IQ's revenue was 1.37 million, an increase of 1254.91% compared to the previous year's 101,409. Losses were -18.57 million, 40.0% more than in 2025.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for EIQ stock is "Buy." The 12-month stock price target is $1.90, which is an increase of 47.86% from the latest price.
News
Echo IQ Annual report: H2 2026
Echo IQ has published its H2 2026 annual report on August 27, 2026.
Echo IQ Transcript: Investor update
Raised AUD 110 million, enabling rapid commercial expansion and R&D acceleration. Over 70 customers and 300 hospitals are in the pipeline, with new pricing programs driving a fivefold increase in proposals. FDA clearance for EchoSolv HF is expected soon, and CMS reimbursement changes are seen as a positive tailwind.
Echo IQ Earnings release: Q4 2026
Echo IQ released its Q4 2026 earnings on July 26, 2026, summarizing the period's financial results.
Research Collaboration Secured to Evaluate AI-Driven Cardiac Risk Stratification in Cancer Patients
Echo IQ's AI platform to be evaluated in collaboration with Mayo Clinic for assessing cardiac risk in patients receiving cancer therapy Echo IQ's AI platform to be evaluated in collaboration with Mayo...
Echo IQ Transcript: Investor update
Expanded commercial agreements with Mayo Clinic and Mount Sinai position the company for rapid U.S. growth pending FDA clearance. The sales pipeline is robust, with high confidence in regulatory and reimbursement progress, and significant revenue ramp expected in the second half of the year.
Echo IQ Announces EchoSolv AS Deployed into Mount Sinai Health System
SYDNEY, April 30, 2026 (GLOBE NEWSWIRE) -- AI and Medical Technology company Echo IQ (“the Company”) (ASX: EIQ) is pleased to advise it has deployed its AI-based decision support software for the asse...
Echo IQ Earnings release: Q3 2026
Echo IQ released its Q3 2026 earnings on April 29, 2026, summarizing the period's financial results.
Echo IQ Quarterly report: H1 2026
Echo IQ has published its H1 2026 quarterly earnings report on February 25, 2026.
Echo IQ Earnings release: Q2 2026
Echo IQ released its Q2 2026 earnings on January 22, 2026, summarizing the period's financial results.
Echo IQ Transcript: Life Sciences Virtual Investor Forum 2025
AI-powered echocardiogram diagnostics are driving rapid commercialization, with FDA clearance for aortic stenosis achieved and heart failure submission underway. Major hospital integrations, a robust product pipeline, and a SaaS model set the stage for significant revenue growth and a potential U.S. IPO in 2026.
Echo IQ to Present at the Life Sciences Virtual Investor Forum on 11th December
Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com Company invites individual and institutional investors, as ...
Echo IQ Transcript: Piper Sandler 37th Annual Healthcare Conference
A novel AI platform enables real-time, highly accurate diagnosis of heart disease from echocardiogram data, with FDA-cleared aortic stenosis detection and a heart failure solution nearing submission. Integration with major hospitals and strong clinical validation support rapid U.S. expansion and revenue growth in 2026.
Echo IQ Transcript: Status Update
EchoSolve HF achieved strong clinical validation with Mayo Clinic, showing 99.5% sensitivity and 91% specificity for heart failure detection. The company is preparing for FDA submission, scaling commercial operations, and leveraging both existing and future reimbursement pathways. Expansion into Europe and Australia is planned post-US clearance.
Echo IQ Slides: Status Update
Echo IQ has posted slides in relation to its latest quarterly earnings report, which was published on November 25, 2025.
Validation study for EchoSolv HF completed at the Mayo Clinic – Study delivers exceptional results
SYDNEY, Nov. 24, 2025 (GLOBE NEWSWIRE) -- AI and Medical Technology Company Echo IQ Limited (ASX: EIQ) (“Echo IQ” or “the Company”) is pleased to advise that it has completed its clinical validation f...
Echo IQ to Participate in the Piper Sandler 37th Annual Healthcare Conference
SYDNEY, Nov. 21, 2025 (GLOBE NEWSWIRE) -- AI and Medical Technology company Echo IQ (“the Company” or “Echo IQ”) (ASX: EIQ), today announced that Dustin Haines, Chief Executive Officer, will participa...